Orca Capital AG's 6.2% Ownership in Silexion Therapeutics Corp

Orca Capital AG, a German entity, has filed a Schedule 13G with the SEC, disclosing a 6.2% ownership in Silexion Therapeutics Corp. The filing indicates that Orca Capital AG beneficially owns 131,250 ordinary shares of Silexion Therapeutics Corp, with sole voting and dispositive power over these shares. The shares are held directly by Orca Capital AG, and the filing certifies that the shares were not acquired for the purpose of influencing the control of the issuer. The filing also notes that Orca Capital AG holds warrants to purchase additional shares, but these are subject to a 4.99% blocker, preventing the entity from exercising the warrants if it would result in ownership exceeding 4.99% of the issuer's outstanding shares. The filing was signed by Thomas Konig, a director of Orca Capital AG, on September 15, 2025.